Throughout the last several years, the 340B Drug Program (340B) and those hospital systems participating in the program have seen several important changing developments. This includes challenges with drug manufacturers and even court rulings which have raised even more questions and impacted participants both financially and in operational aspects. The near future will certainly continue this volatility.

This discussion will provide an update on these recent changes and what issues hospitals need to consider for optimizing their program participation in 2023.

Learning Objectives:

1. Explain the latest updates on contract pharmacy restrictions and allowances by pharmaceutical manufacturers and their impact on discounts and access.

2. Identify how new rules around data sharing and claims data will be used, and how they might impact pricing and HIPAA.

3. Recognize current factors that may have a direct impact on patient definition and eligibility policies and build contingencies to account for those.

4. Demonstrate changes for 340B hospitals under the Outpatient Prospective Payment System (OPPS) and what that will mean for payments and Medicate Part B.